Sanofi aventis to expand manufacturing in Japan

Published: 17-Apr-2008
Manufacturing

Sanofi aventis KK, the Japanese subsidiary of French pharmaceutical company, plans to spend approximately ¥1bn (Euro 6m) to expand the drug manufacturing capabilities of its factory in Kawagoe, Saitama Prefecture.


Sanofi aventis KK, the Japanese subsidiary of French pharmaceutical company, plans to spend approximately ¥1bn (Euro 6m) to expand the drug manufacturing capabilities of its factory in Kawagoe, Saitama Prefecture.

The local unit recently obtained approval to produce Plavix in Japan; with demand rising and its co-marketing agreement with Daiichi Sankyo ending, sanofi aventis has decided to shift production gradually to the Kawagoe factory, which currently produces pills and ampoules of drugs.

The company will install additional tablet coating machinery, bringing its total annual capacity to 2.9 billion tablets.

  • Companies:
  • Sanofi
See more

You may also like

Distribution

Sanofi ramps up Beyfortus shipping ahead of '25–26 RSV season

Read more
Sanofi will boost the availability of the RSV monoclonal antibody vaccine across the US, EU, China and Japan to protect infants from the disease

Trending Articles

  1. Continuous innovation: redefining the future of pharmaceutical manufacturing In an industry in which reliability is paramount and change can be slow, GEA has consistently proven that innovation and stability go hand in hand. Almost two decades ago, GEA introduced the first ConsiGma® continuous manufacturing (CM) system to the pharmaceutical market — a pioneering move that helped to reshape how oral solid dosage (OSD) forms are developed and produced
  2. New 800 sqm microbiology quality laboratory at Aenova Latina site The project adds approximately 500 square meters of new laboratory space, bringing the total to around 800 square meters, and marks a major milestone in the site’s development
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Quality management during manufacturing changes: part I Change is a universal constant and continues to accelerate in the realms of pharmaceutical, medical device and in-vitro diagnostic manufacturers who face ever-increasing pressure to optimise costs while maintaining high product quality and patient safety standards
  4. Watson-Marlow to showcase new Bredel CIP pump and innovative fluid handling solutions at PPMA Watson-Marlow Fluid Technology Solutions (WMFTS) will unveil the new Bredel CIP pump as well as highlight its advanced fluid management technologies during PPMA at the NEC in Birmingham, UK, from 23-25 September 2025
  5. Balancing innovation and accessibility in amino acid testing Butterworth Laboratories expands analytical capabilities to support compliance with Ph. Eur. standards

Upcoming event

Enhancing probiotic stability through smarter formulation and packaging strategies

18 September 2025 | Virtual See all

You may also like

Distribution

Sanofi ramps up Beyfortus shipping ahead of '25–26 RSV season

Sanofi will boost the availability of the RSV monoclonal antibody vaccine across the US, EU, China and Japan to protect infants from the disease
Manufacturing

Sanofi to invest $20bn into US manufacturing capacity following Trump's tariff threats

The company will expand its US pharmaceutical R&D and manufacturing capacity through internal and contract manufacturing investments
Manufacturing

Sanofi opens €558m modular vaccine and biologics manufacturing facility in Singapore

The biopharmaceutical manufacturing facility will allow Sanofi to manufacture up to four vaccines and biologic medicines simultaneously, while also enhancing the area's biopharma supply chain
Manufacturing

Sanofi invests €40m into biopharmaceutical manufacturing at its Lyon Gerland site

The pharma giant has expanded its French monoclonal antibody production capabilities, while also dedicating €25m to the development of a second-gen polyclonal antibody
Manufacturing

Implementing advanced manufacturing technologies for novel therapies

Michele Ghinizzini, Senior Vice President, Global Head of Engineering and Maintenance at Sanofi, explores the elements that enable the realistic implementation of advanced technologies in drug development and manufacturing
Manufacturing

Sanofi and Novavax co-commercialise COVID-19 vaccine

The agreement will aim to commercialise Novavax's adjuvanted COVID-19 vaccination globally, as well as develop a COVID-19 and flu combination vaccine
Manufacturing

Sanofi “all in” on artificial intelligence and data science

“Our ambition is to become the first pharma company powered by artificial intelligence at scale, giving our people tools and technologies," Paul Hudson, CEO of Sanofi
Subscribe now